Three patients with spinal muscular atrophy had improved muscle strength and could walk farther after a month of daily spinal ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal muscle atrophy (SMA), an inherited neuromuscular disease.

The primary endpoint of Part B was the change from baseline on The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders ... higher-dose-regimen-nusinersen 2. Spinal Muscular ...

SPINRAZA is an approved treatment for spinal muscular atrophy in over 71 countries ... vomiting and back pain. Laboratory tests can monitor for renal toxicity and coagulation abnormalities ...

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy (SMA ... met its primary endpoint when testing the intrathecal formulation of ...

Spinal muscular atrophy (SMA) is a rare hereditary neuromuscular ... in 2022', when a Covid-19 outbreak in Shanghai led to mass testing and strict lockdown conditions. Even more worryingly ...

From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...

A case report described an infant with concurrent HDFN and SMA who was succesfully treated with an onasemnogene abeparvovec ...

NEW YORK – Dutch biotech firm MRC Holland said Wednesday that it has received CE marking under the EU's In Vitro Diagnostic Regulation for a molecular test that is used to screen newborns for spinal ...

"The primary endpoint of Part B measured the change from baseline on [Children's Hospital of Philadelphia-Infant Test of Neuromuscular Disorders ... FDA approves first drug for spinal muscular atrophy ...